Test Price
2,800 AED✅ Home Collection Available
GNAS Gene Pseudopseudohypoparathyroidism Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين GNAS (Pseudopseudohypoparathyroidism) بتسلسل الجيل التالي (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – Diagnostic Confidence, Privacy & UAE Compliance
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM - 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed consultant.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
يوفر هذا الاختبار الجيني الدقيق تشخيصًا موثوقًا بدرجة نقاء عالية مع استشارة وراثية مهنية لحماية خصوصية المعلومات الجينية وفقًا للقوانين المحلية (المرسوم بقانون اتحادي رقم 41 لسنة 2024، وقانون حماية البيانات الشخصية).
نظرة عامة | Overview
This single-gene NGS test comprehensively analyzes the GNAS gene for pseudopseudohypoparathyroidism—a rare endocrine disorder within the Albright hereditary osteodystrophy spectrum—ensuring precise differentiation from pseudohypoparathyroidism. يقدم الاختبار تحليلاً كاملاً لجين GNAS لتشخيص دقيق ومبكر يدعم الرعاية السريرية المخصصة.
| Feature | Our ISO NGS Test | Closest Alternative (Sanger) |
|---|---|---|
| Method | NGS (Next Generation Sequencing) | Sanger Sequencing (limited regions) |
| Diagnostic Precision | 99.9% coverage of all GNAS exons & splice sites | High for targeted mutations, may miss deep intronic variants |
| Turnaround Time | 3 – 4 Weeks | 2 – 3 Weeks |
| Accreditation | ISO 9001:2015 + DHA Licensed | Variable; often lacks ISO certification |
| UAE Legal Compliance | Full PDPL & Federal Decree-Law No. 41/2024 adherence | May not meet local genomic data regulations |
Important Pre‑Test Preparation & Sample Requirements
Clinical History & Genetic Counselling:
- A detailed medical and family history for pseudopseudohypoparathyroidism features must be provided.
- Mandatory one‑on‑one genetic counselling session (DHA‑guided) to draw a pedigree chart and obtain informed consent.
Accepted Sample Types:
- Whole Blood (EDTA tube)
- Extracted DNA (minimum concentration 50 ng/µL)
- Single drop blood on FTA Card (hospital‑grade collection only)
No medication or supplement cessation is required; however, anticoagulants must be disclosed to the phlebotomist.
Physician Insight & Safety Protocol
“Every GNAS variant must be interpreted in the clinical context of Albright hereditary osteodystrophy. As an endocrinologist and geneticist, I advise that this test is a powerful tool when combined with a thorough phenotypic assessment; a negative result does not exclude related disorders. Please continue all prescribed medications and attend your specialist follow‑up to correlate the genetic findings with your health status.”
— Dr. PRABHAKAR REDDY, Consultant Endocrinologist & Clinical Geneticist (DHA License: 61713011)
Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria:
- Patients unable to provide informed consent or lacking a legally authorised representative.
- Minors (<18) without court‑appointed guardian consent, as mandated by CDS Law 2026.
- Specimens that do not meet cold‑chain requirements or are haemolysed.
ER Red Flags — Seek immediate medical attention if:
- You are currently experiencing severe hypocalcaemia symptoms (tetany, seizures, cardiac arrhythmia) – this genetic test is elective and not for acute diagnosis.
- You develop sudden mental status changes, atypical fractures, or signs of severe mineral imbalance.
- A genetic report indicating a pathogenic GNAS variant is accompanied by alarming physical symptoms – contact your doctor immediately.
Patient FAQ & Clinical Guidance
Q: What is the GNAS gene pseudopseudohypoparathyroidism test?
Answer: The NGS test screens full GNAS gene mutations causing Albright hereditary osteodystrophy variants, including pseudopseudohypoparathyroidism, using a single blood or DNA sample for comprehensive diagnosis.
This advanced genetic test reads the entire coding region of the GNAS gene to detect even rare pathogenic variants that explain your clinical features. It differentiates pseudopseudohypoparathyroidism (normal calcium) from pseudohypoparathyroidism, guiding appropriate endocrine and genetic management.
س: ما هو اختبار الجين GNAS لمرض القزامة الكاذبة الكاذبة (Pseudopseudohypoparathyroidism)؟
ج: يفحص اختبار التسلسل الجيني الكامل (NGS) طفرات جين GNAS المسببة لمتلازمة أولبرايت الوراثية العظمية، بما فيها القزامة الكاذبة الكاذبة، باستخدام عينة دم أو حمض نووي لتشخيص دقيق.
Q: How accurate is this DNA test?
Answer: The ISO-certified NGS panel achieves >99.9% diagnostic sensitivity for all coding GNAS mutations, enhanced by deep sequencing and rigorous bioinformatics under UAE PDPL privacy safeguards.
Our laboratory utilises Illumina NovaSeq platform with 100x mean coverage, validated against international reference standards, ensuring clinically actionable results. The report includes variant classification per ACMG 2026 guidelines, reviewed by a DHA-licensed specialist.
س: ما مدى دقة هذا الاختبار الجيني؟
ج: يحقق اختبار NGS المعتمد من الآيزو حساسية تشخيصية تزيد عن 99.9% لجميع طفرات GNAS المشفرة، مع حماية كاملة للبيانات الجينية بموجب قانون الإمارات لحماية البيانات الشخصية.
Q: Who should consider this test?
Answer: Individuals with phenotypic features of AHO (short stature, round facies, brachydactyly) and normal calcium to confirm pseudopseudohypoparathyroidism, or those with a family history of such conditions.
This test is also valuable for asymptomatic relatives of affected individuals, couples seeking reproductive genetic counselling, and researchers validating clinical phenotypes. A pre‑ consultation with an endocrinologist or clinical geneticist is mandatory.
س: من الذي يجب أن يفكر في إجراء هذا الاختبار؟
ج: الأفراد الذين تظهر عليهم سمات متلازمة أولبرايت (قصر القامة، الوجه المستدير، قصر الأصابع) مع مستوى كالسيوم طبيعي، أو من لديهم تاريخ عائلي، لتأكيد تشخيص القزامة الكاذبة الكاذبة.
Regulatory Assurance & UAE Legal Framework
This service is fully compliant with Federal Decree‑Law No. 41 of 2024 (Article 87) on Medical Liability, the CDS Law 2026 concerning genetic testing in minors, and the UAE Personal Data Protection Law (PDPL) for genomic data confidentiality. All processes adhere to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA facility license 9834453.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians